In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Dyax finds antibodies against AstraZeneca target

Executive Summary

During a collaborative research project, Dyax will use its antibody phage display technology to identify, characterize, and optimize antibodies that bind specifically to an AstraZeneca neurological and metabolic disease target.
Deal Industry
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register